Avalon GloboCare Corp. (NASDAQ:ALBT) Short Interest Update

Avalon GloboCare Corp. (NASDAQ:ALBT) saw a large drop in short interest during the month of June. As of June 30th, there was short interest totalling 148,000 shares, a drop of 27.1% from the June 15th total of 202,900 shares. Currently, 3.3% of the shares of the company are short sold. Based on an average daily volume of 2,760,000 shares, the short-interest ratio is currently 0.1 days.

Avalon GloboCare Stock Performance

NASDAQ ALBT opened at $0.48 on Monday. The firm’s fifty day moving average is $0.43 and its two-hundred day moving average is $0.39. Avalon GloboCare has a one year low of $0.24 and a one year high of $1.70. The firm has a market cap of $5.36 million, a PE ratio of -0.34 and a beta of 0.32.

Avalon GloboCare (NASDAQ:ALBT) last issued its quarterly earnings results on Thursday, May 30th. The company reported ($0.12) earnings per share (EPS) for the quarter. The company had revenue of $0.32 million during the quarter.

About Avalon GloboCare

Avalon GloboCare Corp., together with its subsidiaries, owns and operates commercial real estate properties in the United States and China. The company develops and delivers transformative cellular therapeutics, precision diagnostics, and clinical laboratory services. Its leading candidates are AVA-001, an anti-CD19 CAR-T, which has completed first-in-human clinical trial for relapsed/refractory (R/R) B-cell lymphoblastic leukemia; and AVA-011 that has completed pre-clinical laboratory studies and undergoing IND-enabling process development stage to generate cGMP-grade AVA-011 CAR-T cells.